MedPath

Efficacy Study of Acupuncture on Asymptomatic Hyperuricemia

Not Applicable
Recruiting
Conditions
Asymptomatic Hyperuricemia
Interventions
Behavioral: health education
Device: verum acupuncture
Device: sham acupuncture
Registration Number
NCT05406830
Lead Sponsor
Lingling Yu (103250)
Brief Summary

hyperuricemia (HUA) is an important risk factor for various chronic diseases, such as gout, and the current treatment programs for HUA are not ideal. It is urgent to find new methods to prevent and treat HUA and to carry out early clinical intervention. Acupuncture is commonly used for the treatment of HUA, while the evidence for its efficacy is still uncertain. This clinical trial aimed to evaluate the efficacy and safety of manual acupuncture for asymptomatic HUA.

Detailed Description

This is a multicentre, stratified, randomized, sham-controlled clinical trial. 180 eligible participants will be randomly allocated into verum acupuncture group or sham acupuncture group, in a 1:1 ratio. The verum acupuncture group will receive 16 sessions of manual acupuncture treatments over an eight-week period, while the sham acupuncture group will receive sham acupuncture treatments with non-penetrating needling. Health education will be provided to participants in the two groups. The primary outcomes will be the changes in the mean levels of serum uric acid 8 weeks after randomization. The secondary outcomes will be the changes in the mean levels of serum uric acid 4, 12, 16, and 20 weeks after randomization. Other secondary outcomes included effective rates, the proportion of patients with acute gouty arthritis, changes in body weight and BMI, safety evaluation and deqi evaluation. The central randomization and data collection will be conducted by an electronic data management system.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
180
Inclusion Criteria
  • Diagnosed as hyperuricemia; and
  • Fasting blood uric acid level ≥ 7-11.0 mg/dL after 1 month of low-purine diet; and
  • Without history of gouty arthritis; and
  • Without drug treatment for hyperuricemia or stop uric acid-lowering drug treatment ≥12 weeks; and
  • 18.5kg/m2≤BMI≤30.0kg/ m2; and
  • Able to signing a informed consent.
Exclusion Criteria
  • Those who are using or have used one of the following drugs for the treatment of hyperuricemia 12 weeks before eligibility evaluation, such as: allopurinol, benzbromarone, probesulfan, bugelone, toppirosteine, Busotan; and
  • Patients are using or used other drugs that affect uric acid metabolism in the past 12 weeks, such as: thiazide diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, compound reserpine, pyrazinamide, nitrates fendipine, propranolol, and benzbromarone; and
  • Patients have history of gouty arthritis; and
  • Combined with secondary hyperurmicema, such as bone marrow and lymphoproliferative diseases, tumor radiotherapy and chemotherapy, liver cirrhosis and drug-induced hyperurmicema; and
  • Combined with one of the following comorbidities: hypertension, diabetes, stroke, coronary heart disease, severe liver and kidney damage (≥CKD stage 2, or high creatinine, urea, glutamate, glutamate ≥ 2 times of the limit of clinical normal values); and
  • Combined with severe neuropsychological diseases, such as severe anxiety, depression, and intellectual disability; and
  • Pregnant women; and
  • Unwilling to accept acupuncture treatment; and
  • Illiterate, or patients unable to sign informed consent; and
  • The completion rate of baseline screening data is ≤80%.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Sham acupuncture (SA)health educationParticipants will be treated by non-penetrating sham acupuncture and usual care. They will be treated twice a week for 8 weeks, to fulfill a 16-session treatment course. Each acupuncture treatment session for patients will be 30 minutes in duration.
Sham acupuncture (SA)sham acupunctureParticipants will be treated by non-penetrating sham acupuncture and usual care. They will be treated twice a week for 8 weeks, to fulfill a 16-session treatment course. Each acupuncture treatment session for patients will be 30 minutes in duration.
Verum acupuncture (VA)verum acupunctureParticipants will be treated by real manual acupuncture and usual care. They will be treated twice a week for 8 weeks, to fulfill a 16-session treatment course. Each acupuncture treatment session for patients will be 30 minutes in duration.
Verum acupuncture (VA)health educationParticipants will be treated by real manual acupuncture and usual care. They will be treated twice a week for 8 weeks, to fulfill a 16-session treatment course. Each acupuncture treatment session for patients will be 30 minutes in duration.
Primary Outcome Measures
NameTimeMethod
Changes in the mean level of serum uric acid from baseline.At baseline, and at 8 weeks after randomization.

The changes in the mean level of serum uric acid at 8 weeks after randomization compared to baseline

Secondary Outcome Measures
NameTimeMethod
Safety evaluationImmediately following each session of acupuncture treatment.

Adverse events during the acupuncture process

The proportion of patients with acute gouty arthritisWeeks 1-4 after randomization, weeks 5-8 after randomization, weeks 9-12 after randomization, weeks 13-16 after randomization, and weeks 17-20 after randomization.

The proportion of patients with acute gouty arthritis per 4-week cycle after randomization.

Changes in body weight of patients4, 8, 12, 16 and 20 weeks after randomization

Changes in body weight of patients at 4, 8, 12, 16, and 20 weeks after randomization.

Effective rate of patients with serum uric acid ≤ 6.0 mg/dL4, 8, 12, 16 and 20 weeks after randomization

The ratio of patients with serum uric acid ≤ 6.0 mg/dL at weeks 4, 8, 12, 16 and 20 after randomization

Changes in the mean level of serum uric acid from baseline.At baseline, at 4, 12, 16, and 20 weeks after randomization.

The changes in the mean level of serum uric acid at 4, 12, 16, 20 weeks after randomization compared to baseline

Effective rate of patients with serum uric acid ≤ 7.0 mg/dL4, 8, 12, 16 and 20 weeks after randomization

The ratio of patients with serum uric acid ≤ 7.0 mg/dL at weeks 4, 8, 12, 16 and 20 after randomization

Arrival of qi assessmentImmediately following each session of acupuncture treatment.

The Chinese Version of the Massachusetts General Hospital Acupuncture Sensation Scale Acupuncture sensations will be measured by the Massachusetts General Hospital (MGH) Acupuncture Sensation Scale (MASS)

Changes in the dose of intake of acute medication.Weeks 1-4 after randomization, weeks 5-8 after randomization, weeks 9-12 after randomization, weeks 13-16 after randomization, and weeks 17-20 after randomization.

The changes in the dose of intake of acute medication per 4-week cycle after randomization.

Trial Locations

Locations (1)

Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

🇨🇳

Wuhan, Hubei, China

© Copyright 2025. All Rights Reserved by MedPath